% 0期刊文章%一个莱利波维% Liene Elsone %一个娜迪亚Borisow恩里克·阿尔瓦雷斯% %梅丽莎·科尔特斯%一个法拉Mateen %一个Maureen粉% Jaime Sorum %一个克里帽子%肖恩Tobyne % Klemens•鲁普雷希特迈克尔·利维%一个扣% %一个保罗Friedemann院长Wingerchuk % % %安妮十字布莱恩Weinshenker %一个阿奴雅各% Eric Klawiter % Tanuja Chitnis % T激素暴露与临床表型的女性视Neuromyelitis (S12.005) % D J神经病学2016% % P S12.005 X % V % 86% N 16补充目的:研究激素暴露与疾病之间的关联特征的女性视Neuromyelitis谱系障碍(NMOSD)。首页背景:女性比男性在NMOSD 9:1但性别激素的作用在动疾病发病机理尚未研究。设计/方法:标准化管理与NMOSD女性生殖调查8点(82 (percnt)抗体阳性)临床中心,其次是图表回顾。使用多变量回归,我们检查生殖之间的关系曝光和两个临床结果:年龄首先出现症状(FS),和扩大残疾状态量表(eds)在最后一次访问。对于后者,我们调整了年龄和疾病持续时间。结果:在217名受访者中,在月经初潮平均年龄为12.8岁(1.7 SD),怀孕的平均数是2.1(标准差1.7),包括0.3(标准差0.7)发生后动的诊断。在117绝经后的主题,70 [percnt]报道自然绝经(平均年龄:48.9岁(SD - 3.9));少于30 [percnt]报道全身激素治疗(HT)使用。14.2 FS年龄为40.1岁(SD)。曾经使用系统性激素类避孕药(HC)早些时候与略微FS(39和43年,p = 0.05)。 A later FS was associated with a greater number of preceding pregnancies (p=0.0004), but the confounding effect of subject age on both variables could not be accounted for. Mean clinical severity (EDSS) at last visit (median disease duration: 7 years) was 4 (median 3.5, SD 2.2). Ever-use of HC was associated with better EDSS (p=0.002). In postmenopausal subjects, ever-use of HT also was associated with better EDSS (p=0.04, also adjusting for menopausal age and type) and use of HC was no longer significant (p=0.50). Conclusions: In this study, exogenous hormonal exposures, including HC and HT, were associated with earlier age of NMOSD onset but lower disability. Further studies should assess whether this association is causative.Disclosure: Dr. Bove has nothing to disclose. Dr. Elsone has nothing to disclose. Dr. Alvarez has received personal compensation for activities with Teva Neuroscience, Biogen, Genzyme, Genentech, and Novartis. Dr. Borisow has nothing to disclose. Dr. Cortez has nothing to disclose. Dr. Mateen has nothing to disclose. Dr. Mealy has nothing to disclose. Dr. Sorum has nothing to disclose. Dr. Mutch has nothing to disclose. Dr. Tobyne has nothing to disclose. Dr. Ruprecht has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi/Genzyme, Teva, Roche, and Novartis. Dr. Buckle received personal compensation for activities with Accorda Therapeutics, Bayer Healthcare, Biogen-Idec, EMD-Serono, Novartis, Genzyme Corporation, Questcor, and Teva Neuroscience as a consultant. Dr. Levy has received personal compensation for activities with Alexion, Guidepoint Global, and Genzyme. Dr. Levy has received research support from Acorda Therapeutics, Sanofi, Alexian, TG Therapeutics, and TerumoBCT. Dr. Wingerchuk has received personal compensation for serving on a clinical trial adjudication committee for Medimmune. Dr. Wingerchuk has received personal compensation in an editorial capacity for The Neurologist. Dr. Wingerchuk has received research su Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Bayer Schering Pharma, Merck Serono, Biogen Idec, Medimmune, and Novartis. Dr. Cross has received personal compensation for activities with Biogen Idec, Genzyme Corporation, GlaxoSmithKline, Inc., Hoffman-La Roche, Teva Neuroscience, Novartis, and Questcor. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, Mitsubishi Pharmaceuticals, MedImmune Pharmaceuticals, Chugai, and Chord as a consultant. Dr. Weinshenker has received royalty payments from RSR Ltd. and Oxford Dr. Jacob has nothing to disclose. Dr. Klawiter has received personal compensation for activities with Biogen Idec and Mallinckrodt Pharmaceuticals as a consultant. Dr. Chitnis has received personal compensation for activities with Novartis and Biogen. Dr. Chitnis has received research support from Merck-Serono and Novartis Pharmaceuticals.Sunday, April 17 2016, 1:00 pm-3:00 pm %U